+ 654.59
+ 1.37%

Where Jazz Pharmaceuticals Stands With Analysts

June 22, 2021 11:50 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago
Bullish 0 1 1 1
Somewhat Bullish 1 1 0 0
Indifferent 0 0 0 1
Somewhat Bearish 0 0 0 0
Bearish 0 0 0 0

In the last 3 months, 9 analysts have offered 12-month price targets for Jazz Pharmaceuticals. The company has an average price target of $214.78 with a high of $250.00 and a low of $176.00.

price target chart

This current average has increased by 8.41% from the previous average price target of $198.11.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts also give out recommendations like “buy”, “sell”, “hold”, or similar verbage for each stock based on their overall evaluations of the corres ponding company. A “buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth, recommending traders to purchase the stock. Contrastingly, a “sell” means that an analyst believes the stock will trend downwards in that same time frame. A “hold” suggests that investors should not buy more of or sell any of the specified stock due to that analyst’s prediction of stagnation.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Analyst Ratings

Related Articles

10 Biggest Price Target Changes For Monday

10 Biggest Price Target Changes For Monday

UBS boosted the price target on Seagate Technology Holdings plc (NASDAQ: STX) from $83 to $105. Seagate shares rose 0.8% to $91.05 in pre-market trading. read more

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $210

HC Wainwright & Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $220 to $210. read more
10 Biggest Price Target Changes For Tuesday

10 Biggest Price Target Changes For Tuesday

Goldman Sachs lowered Casey's General Stores, Inc. (NASDAQ: CASY) price target from $240 to $215. Casey's shares rose 2.5% to close at $201.89 on Monday. read more

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $250

Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $235 to $250. read more